|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Imatron (IMAT) is up 9/16, closed at 2-17/32,
volume 6,601,700 shrs traded vs. average 900K shares daily
Today (2/8/96), Cruttenden Roth analyst William
Prather initiated coverage of the company at a buy rating.
The South San Francisco, Calif., company develops and manufactures
computed tomography scanners.
In a research note, Cruttenden said it believes the company's
ultrafast computer tomography scanning technology will
emerge as the new standard for screening patients
for coronary artery disease.
The brokerage firm estimates a loss of 11 cents a share in
1996 and net income of 7 cents in 1997, and its 12-month price
target is 4 3/4.
check it out
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|